The literature also found that CXCL13 shapes an immunoreactive TME by facilitating the maintenance of CXCR5+CD8+ T cells in TLSs, and the combination of CXCL13 and anti-PD-1 significantly inhibited tumor growth in subcutaneous murine models of ovarian cancer (55). This evidence concerns the gene CXCL13 and ovarian carcinoma.